Merck Sharp & Dohme Corp

Inhibrx Biosciences Advances Two Oncology Programs with Key Enrollment Milestones and Upcoming Data Readouts

- Inhibrx has recruited 46 of 60 patients in its Phase 2/3 trial evaluating INBRX-106 plus Keytruda versus Keytruda alone for first-line treatment of head and neck squamous cell carcinoma, with enrollment completion expected in Q1 2026. - The company completed enrollment of 34 patients in November 2025 for its Phase 1/2 trial of INBRX-106 plus Keytruda in checkpoint inhibitor refractory or relapsed non-small cell lung cancer. - Ozekibart expansion cohorts show progress with 44 patients enrolled in colorectal cancer combination therapy, demonstrating well-tolerated treatment with durable responses and high disease control rates. - Data maturity for both INBRX-106 programs is expected in the second half of 2026, while ozekibart progression-free survival data should mature in Q2 2026.